ArticleFrontiers in neurology2026
Higher serum uric acid levels are associated with improved outcomes in acute ischemic stroke patients following intravenous thrombolysis with alteplase-a retrospective cohort study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence suggests that hyperuricemia may serve as a predictor of favorable outcomes in acute ischemic stroke (AIS) patients receiving endovascular treatment; however, the relationship between serum uric acid (SUA) levels and clinical outcomes in AIS patients treated with intravenous thrombolysis (IVT) remains underexplored. Methods: In this retrospective study, we analyzed AIS patients who underwent IVT with alteplase within 4.5 h of symptom onset, excluding those undergoing subsequent endovascular intervention, at our hospital between November 2021 and December 2024. Data collection encompassed baseline demographic and clinical characteristics, SUA levels measured within 24 h post-thrombolysis, and neuroimaging findings from cranial computed tomography and magnetic resonance scans. The primary outcome was defined as an excellent 90-day functional outcome, characterized by a modified Rankin Scale (mRS) score of 0-1. Results: Among 194 screened patients, 130 were included in the final analysis. Of these, 87 patients (66.92%) achieved an excellent 90-day outcome. Multivariable logistic regression analysis, adjusted for potential confounders, revealed that patients with higher SUA levels (>360 μmol/L) exhibited a significantly higher likelihood of achieving an excellent 90-day outcome (adjusted OR: 2.690, 95% CI: 1.082-6.685, Conclusion: These findings indicate that higher SUA levels are significantly associated with improved 90-day functional outcomes in AIS patients treated with alteplase thrombolysis within 4.5 h of symptom onset.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.